FGFR2 and endometrial cancer: For example, a point mutation in FGFR3 is detected in 50% to 60% of non-muscle, invasive urothelial carcinomas [4], whereas missense activating mutations of the extracellular domain in FGFR2 are documented in 12% to 14% of endometrial cancer cases [5,6]; (ii) FGFR gene amplification and overexpression, which triggers excessive FGFR-mediated signaling.